Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: vandecasteele k. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G. Vandecasteele K, et al. Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925. Int J Gynecol Cancer. 2012. PMID: 22237382
Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results.
Tummers P, Makar A, Vandecasteele K, De Meerleer G, Denys H, De Visschere P, Delrue L, Villeirs G, Lambein K, den Broecke RV. Tummers P, et al. Among authors: vandecasteele k. Int J Gynecol Cancer. 2013 Jun;23(5):877-83. doi: 10.1097/IGC.0b013e31828d1ec0. Int J Gynecol Cancer. 2013. PMID: 23698797
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Makar AP, et al. Among authors: vandecasteele k. Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009938 Free PMC article. Review.
Immunogenic Apoptotic Cell Death and Anticancer Immunity.
Vandenabeele P, Vandecasteele K, Bachert C, Krysko O, Krysko DV. Vandenabeele P, et al. Among authors: vandecasteele k. Adv Exp Med Biol. 2016;930:133-49. doi: 10.1007/978-3-319-39406-0_6. Adv Exp Med Biol. 2016. PMID: 27558820 Review.
EXclusion of non-Involved uterus from the Target Volume (EXIT-trial): an individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques.
Vandecasteele K, Tummers P, Van Bockstal M, De Visschere P, Vercauteren T, De Gersem W, Denys H, Naert E, Makar A, De Neve W. Vandecasteele K, et al. BMC Cancer. 2018 Sep 17;18(1):898. doi: 10.1186/s12885-018-4800-0. BMC Cancer. 2018. PMID: 30223802 Free PMC article. Clinical Trial.
69 results